inclisiran
Showing 26 - 33 of 33
Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic
Recruiting
- Atherosclerosis
- Aortic Valve Disease
- Thrombotic assessment
- Measurement of Lp(a)
-
Stevenage, United KingdomEast and North Herts NHS Trust
Nov 6, 2023
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol Trial in Worldwide (Inclisiran, Placebo)
Completed
- Heterozygous Familial Hypercholesterolemia
- Elevated Cholesterol
- Inclisiran
- Placebo
-
Mission Viejo, California
- +44 more
Oct 6, 2020
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia Trial in Worldwide (Inclisiran Sodium)
Active, not recruiting
- ASCVD
- +3 more
- Inclisiran Sodium
-
Birmingham, Alabama
- +237 more
Jan 26, 2022
ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol Trial in Worldwide (Inclisiran Sodium, Placebo)
Completed
- ASCVD
- +2 more
- Inclisiran Sodium
- Placebo
-
Chomutov, Czechia
- +69 more
Aug 3, 2020
ASCVD, Elevated Cholesterol Trial in United States (Inclisiran Sodium, Placebo)
Completed
- ASCVD
- Elevated Cholesterol
- Inclisiran Sodium
- Placebo
-
Birmingham, Alabama
- +144 more
Sep 8, 2020
Renal Impairment Trial in Auckland, Christchurch (Inclisiran)
Completed
- Renal Impairment
- Inclisiran
-
Auckland, New Zealand
- +1 more
Nov 8, 2018
Homozygous Familial Hypercholesterolemia Trial in Los Angeles, Amsterdam, Parktown (ALN-PCSSC, Standard of Care)
Completed
- Homozygous Familial Hypercholesterolemia
- ALN-PCSSC
- Standard of Care
-
Los Angeles, California
- +2 more
May 14, 2020
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes Trial in Worldwide (ALN-PCSSC, Normal Saline)
Completed
- Atherosclerotic Cardiovascular Disease
- +2 more
- ALN-PCSSC
- Normal Saline
-
Jacksonville, Florida
- +53 more
Apr 23, 2019